USA - New York Stock Exchange - NYSE:AVTR - US05352A1007 - Common Stock
The current stock price of AVTR is 10.93 USD. In the past month the price decreased by -3.45%. In the past year, price decreased by -48.9%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.57 | 215.20B | ||
| DHR | DANAHER CORP | 29.35 | 159.81B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 186.35 | 56.63B | ||
| A | AGILENT TECHNOLOGIES INC | 26.07 | 41.25B | ||
| IQV | IQVIA HOLDINGS INC | 19.42 | 38.46B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.82 | 28.91B | ||
| WAT | WATERS CORP | 31.09 | 23.50B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.64 | 20.16B | ||
| ILMN | ILLUMINA INC | 29.58 | 19.71B | ||
| MEDP | MEDPACE HOLDINGS INC | 38.33 | 15.44B | ||
| TEM | TEMPUS AI INC | N/A | 13.64B | ||
| RVTY | REVVITY INC | 21.04 | 11.43B |
Avantor, Inc. is a life science tools company that engages in providing mission-critical products and services to the life sciences and advanced technology industries. The company is headquartered in Radnor, Pennsylvania and currently employs 13,500 full-time employees. The company went IPO on 2019-05-17. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
AVANTOR INC
Radnor Corporate Center, Building One, Suite 200, 100 Matsonford Road
Radnor PENNSYLVANIA 19087 US
CEO: Michael Stubblefield
Employees: 13500
Phone: 16103861700
Avantor, Inc. is a life science tools company that engages in providing mission-critical products and services to the life sciences and advanced technology industries. The company is headquartered in Radnor, Pennsylvania and currently employs 13,500 full-time employees. The company went IPO on 2019-05-17. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
The current stock price of AVTR is 10.93 USD. The price decreased by -1.97% in the last trading session.
AVTR does not pay a dividend.
AVTR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
26 analysts have analysed AVTR and the average price target is 13.84 USD. This implies a price increase of 26.64% is expected in the next year compared to the current price of 10.93.
The Revenue of AVANTOR INC (AVTR) is expected to decline by -4.16% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
AVANTOR INC (AVTR) currently has 13500 employees.
ChartMill assigns a fundamental rating of 4 / 10 to AVTR. AVTR has a medium profitability rating, but doesn't score so well on its financial health evaluation.
Over the last trailing twelve months AVTR reported a non-GAAP Earnings per Share(EPS) of 0.96. The EPS decreased by -2.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.7% | ||
| ROE | -1.48% | ||
| Debt/Equity | 0.65 |
26 analysts have analysed AVTR and the average price target is 13.84 USD. This implies a price increase of 26.64% is expected in the next year compared to the current price of 10.93.
For the next year, analysts expect an EPS growth of -8.14% and a revenue growth -4.16% for AVTR